EC
PTGX icon

EcoR1 Capital’s Protagonist Therapeutics PTGX Stock Holding History

EcoR1 Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-381,711
Closed -$9.04M – 91
2022
Q1 		$9.04M Sell
381,711
-2,257,995
-86% -$63.6M 0.28% 43
2021
Q4 		$90.3M Buy
2,639,706
+1,195,906
+83% +$37.8M 2.88% 10
2021
Q3 		$25.6M Buy
+1,443,800
New +$61.6M 0.89% 21
2018
Q2 		– Sell
-1,083,567
Closed -$9.31M – 39
2018
Q1 		$9.31M Buy
+1,083,567
New +$20.4M 0.93% 24

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EcoR1 Capital's PTGX Position: Q2 2022 in Review

EcoR1 Capital sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 381,711 shares — an estimated $9.04M sold.

EcoR1 Capital first reported a position in PTGX in Q1 2018 and held it in 4 quarters. The position peaked at $90.3M in Q4 2021. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

  • EcoR1 Capital reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
  • EcoR1 Capital sold 381,711 Protagonist Therapeutics shares in Q2 2022, an estimated $9.04M.
  • EcoR1 Capital first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 4 quarters.
  • EcoR1 Capital's Protagonist Therapeutics position peaked at $90.3M in Q4 2021.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.